Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9 By: Renalytix plc via GlobeNewswire June 05, 2023 at 07:00 AM EDT LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call. Webcast Registration link: https://edge.media-server.com/mmc/p/u32tnka9 For further information, please contact: Renalytix plc www.renalytix.comJames McCullough, CEOVia Walbrook PR Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc (Joint Broker)Tel: 020 7597 4000Gary Clarence / Shalin Bhamra Walbrook PR LimitedTel: 020 7933 8780 or renalytix@walbrookpr.comPaul McManus / Lianne ApplegarthMob: 07980 541 893 / 07584 391 303 CapComm Partners Peter DeNardoTel: 415-389-6400 or investors@renalytix.com About RenalytixRenalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com. Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9 By: Renalytix plc via GlobeNewswire June 05, 2023 at 07:00 AM EDT LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call. Webcast Registration link: https://edge.media-server.com/mmc/p/u32tnka9 For further information, please contact: Renalytix plc www.renalytix.comJames McCullough, CEOVia Walbrook PR Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc (Joint Broker)Tel: 020 7597 4000Gary Clarence / Shalin Bhamra Walbrook PR LimitedTel: 020 7933 8780 or renalytix@walbrookpr.comPaul McManus / Lianne ApplegarthMob: 07980 541 893 / 07584 391 303 CapComm Partners Peter DeNardoTel: 415-389-6400 or investors@renalytix.com About RenalytixRenalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call. Webcast Registration link: https://edge.media-server.com/mmc/p/u32tnka9 For further information, please contact: Renalytix plc www.renalytix.comJames McCullough, CEOVia Walbrook PR Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc (Joint Broker)Tel: 020 7597 4000Gary Clarence / Shalin Bhamra Walbrook PR LimitedTel: 020 7933 8780 or renalytix@walbrookpr.comPaul McManus / Lianne ApplegarthMob: 07980 541 893 / 07584 391 303 CapComm Partners Peter DeNardoTel: 415-389-6400 or investors@renalytix.com About RenalytixRenalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
